Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.
Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.
Investors
4:00 PM EDT • Aug 18, 2022
QTNT
0.2073USD
-5.77%
Contact
Ali Kiboro, Chief Financial Officer
IR@quotientbd.com
3 Months
6 Months
12 Months
Quotient Ltd
$
Events & Presentations
Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update
June 24, 2022
Events & presentations
Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call
Press releases
Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu